implantable cardioverter defibrillator


Also found in: Acronyms.

implantable cardioverter defibrillator

A defibrillator designed to treat a cardiac tachyarrhythmia directly. If a patient has a ventricular defibrillator and the device senses a ventricular rate that exceeds the programmed cut-off rate of the defibrillator, the device performs cardioversion/defibrillation. Alternatively, the device, if so programmed, may attempt to pace rapidly for a number of pulses, usually around 10, to attempt pace-termination of a ventricular tachycardia.
References in periodicals archive ?
9 - Set for implantable cardioverter defibrillator jednojamowego of enlarged; hv pulse configuration and delivered defibrillation energy =36 J;
SAN DIEGO--Cutting-edge implantable cardioverter defibrillators improve patient quality of life, functional Capacity, and exercise tolerance, according to a study presented at the annual meeting of the North American Society of Pacing and Electrophysiology
The report by TechNavio Insights forecasts the size of the global implantable cardioverter defibrillator (ICD) over the period 2008-2012.
implant of its line of Extended Longevity (EL) implantable cardioverter defibrillators (ICD), including DYNAGEN(TM) EL and INOGEN(TM) EL device models.
10 - Set the implantable cardioverter defibrillator dwujamowego of telemonitoringiem of defibrillation energy 35 J.
1 Long-term outcome of patients who receive implantable cardioverter defibrillators for stable ventricular tachycardia.
Growth in this sector is anticipated to grow despite continuing product recalls and safety controversies, particularly in the Implantable Cardioverter Defibrillators, Implantable Cardiac Pacemakers segment.
Jude Medical's high-output Atlas(TM) ICD family for unsurpassed power in rate-adaptive dual- and single-chamber implantable cardioverter defibrillator therapy.
18 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) announced today that it has performed a successful pre- clinical implantation of its Sentinel 2000 implantable cardioverter defibrillator (ICD) at the University of Minnesota.
NYSE:STJ) today announced publication of the OPTIC (Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients) clinical study results in the January 11 edition of The Journal of the American Medical Association (JAMA).
Food and Drug Administration (FDA) market approval of its VITALITY(R) HE implantable cardioverter defibrillator.

Full browser ?